{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:32:14Z","timestamp":1790253134428,"version":"4.1.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,24]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Appropriate usage of highly active antiretroviral therapy (HAART) suppresses human immunodeficiency virus (HIV) replication. One of such HAART is dolutegravir (DTG) containing regimen which Nigeria included in her national protocol, as the preferred first-line option, with particularly fixed dose combination of tenofovir\/lamivudine\/dolutegravir (TLD) in 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>To access the impact of this regimen as against other regimens on some hematological parameters as well as cluster of differentiation 4 (CD4) count and viral load on people living with HIV infection<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The study site is a health facility center supported by President Emergency Plan for acquired immunodeficiency syndrome (AIDS) Relief where people living with HIV infection (PLWHIV) visit for their routine management in Abakaliki, Ebonyi State. A hundred and twenty-two (122) subjects participated, 58 PLWHIV and 64 control subjects. CD4 + count by partec cyflow auto analyzer, while the Viral load assay was by Roche COBAS Ampriplep\/COBAS TaqMan molecular systems. Full blood count determination was by Sysmex XE-2100 hematology auto analyzer, while the detection of antibody to HAART was by Petz and direct Coombs tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Mean values of hemoglobin (Hb), Total white cell count, Lymphocytes, Monocytes and CD4 + counts of people living with HIV infection (PLWHIV) were significantly (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .0001) lower than the control subjects. The Hb level of PLWHIV on Efavirenz combination (TDF\/3TC\/EFV) are comparable 123\u2009\u00b1\u200932g\/l with those on Ritonavir combination (TDF\/3TC\/LPV\/R) 136\u2009\u00b1\u200916g\/l and Dolutegravir (TLD)134\u2009\u00b1\u200920.0g\/l (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .307). On the other hand, total white cell count (4.55\u2009\u00b1\u20091.99\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L) of those on Efavirenz combination (TDF\/3TC\/EFV) and Dolutegravir (TLD) (4.53\u2009\u00b1\u20091.31\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L) were significantly higher than those on Ritonavir combination (TDF\/3TC\/LPV\/R) (4.09\u2009\u00b1\u20091.15\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L). The Viral Load of PLWHIV on Dolutegravir (TLD) was significantly lower 171.57\u2009\u00b1\u20094.56 copies\/mL than those on Efavirenz combination (TDF\/3TC\/EFV) (86,395.91\u2009\u00b1\u200927,476.57copies\/mL) and Ritonavir combination (TDF\/3TC\/LPV\/R) (81,188.83\u2009\u00b1\u200913,393.47 copies\/mL), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Some hematological parameters (such as Hb, total white cell counts and CD4 + count) were lower in people living with HIV than values seen in control group. The 3 regimens used in the management of HIV infection in the locality revealed comparable Packed cell volume and Hemoglobin levels. Total white cell count of those on Efavirenz and DTG is comparable with higher values than those on Ritonavir.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000035910","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T14:02:17Z","timestamp":1701698537000},"page":"e35910","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria"],"prefix":"10.1097","volume":"102","author":[{"given":"Stella N.","family":"Echefu","sequence":"first","affiliation":[{"name":"Alex Ekwume Federal University Teaching Hospital Abakaliki, Ebonyi State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Udosen","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Calabar, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euphoria C.","family":"Akwiwu","sequence":"additional","affiliation":[{"name":"Department of Haematology and Blood Transfusion Science, University of Calabar, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine O.","family":"Akpotuzor","sequence":"additional","affiliation":[{"name":"Department of Haematology and Blood Transfusion Science, University of Calabar, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4538-0161","authenticated-orcid":false,"given":"Emmanuel Ifeanyi","family":"Obeagu","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Science, Kampala International University, Uganda."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-20250524","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3201\/eid\/1706.100184","article-title":"Reflections on 30 years of AIDS.","volume":"17","author":"De Cock","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"R6-20250524","doi-asserted-by":"crossref","first-page":"146","DOI":"10.7326\/M17-2252","article-title":"Desperation and Suicidal ideation among HIV infected adult receiving Efavirenz versus Nevirapine in Uganda.","volume":"169","author":"Chang","year":"2018","journal-title":"Ann Intern Med"},{"key":"R7-20250524","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher rate of Neuropyshiatic adverse events leading to dolutegravir discontinuation in women and old patients.","volume":"18","author":"Hoffmn","year":"2017","journal-title":"HIV Med"},{"key":"R8-20250524","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/QAI.0000000000001269","article-title":"Pyschiatricsy symptoms in patients receiving.","volume":"74","author":"Feltiplace","year":"2017","journal-title":"J Acqur Immune Defi syndr"},{"key":"R9-20250524","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1056\/NEJMc1807653","article-title":"Neural tube defects with dolutegravir treatment from the time of conception.","volume":"379","author":"Zash","year":"2018","journal-title":"N Engl J Med"},{"key":"R12-20250524","doi-asserted-by":"crossref","first-page":"e0284767","DOI":"10.1371\/journal.pone.0284767","article-title":"High acceptability and viral suppression rate for first line patients on adolutegravir-based regimen,An early adopter study in Nigeria.","volume":"18","author":"Abudiore","year":"2023","journal-title":"PLoS One"},{"key":"R14-20250524","first-page":"48","article-title":"Determinants of voluntary uptake of HIV counseling and testing among infected persons in Calabar, Nigeria.","volume":"7","author":"Akwiwu","year":"2018","journal-title":"Contemp J Interdiscip Stud"},{"key":"R15-20250524","first-page":"33","article-title":"Prevalence of antibodies to HAART agents among HIV patients in Benin City.","volume":"11","author":"Omorgie","year":"2008","journal-title":"African J Biomed Res"},{"key":"R16-20250524","first-page":"9","article-title":"Profile of haematologial abnormalities of Indian HIV infected individual.","volume":"13","author":"Dikshit","year":"2009","journal-title":"BMC Blooddisorder"},{"key":"R17-20250524","first-page":"65","article-title":"Iron related parameters of HIV -infected patients attending University of Calabar Teaching Hospital, Nigeria.","volume":"15","author":"Okafor","year":"2016","journal-title":"J Dent Med Sci"},{"key":"R18-20250524","first-page":"85","article-title":"P53 protein level and some haematologic parameters among women of reproductive age living with HIV infection.","volume":"36","author":"Akwiwu","year":"2021","journal-title":"Nigerian J Physiol Sci"},{"key":"R19-20250524","first-page":"13","article-title":"HIV associated anaemia before and after initiation of antiretroviral therapy at ART centre of Minilik II Hospital Addis-Ababa Ethiopia.","volume":"50","author":"Adane","year":"2012","journal-title":"Ethiop Med J"},{"issue":"3","key":"R20-20250524","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1021\/jm400674a","article-title":"Inhibiting the HIV integration process: past, present, and the future.","volume":"57","author":"Di Santo","year":"2014","journal-title":"Journal of medicinal chemistry"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T14:00:54Z","timestamp":1748095254000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":13,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035910","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]}}}